Zimberelimab
Product Specifications
UNSPSC Description
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma[1][2].
Target Antigen
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zimberelimab.html
Purity
99.90
Solubility
H2O
Smiles
[Zimberelimab]
References & Citations
[1]Lou B, et al. Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer. Front Oncol. 2021 Sep 15;11:736955.|[2]Markham A. Zimberelimab: First Approval. Drugs. 2021 Nov;81(17):2063-2068.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99109/Zimberelimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99109/Zimberelimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2259860-24-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
LV2091 1 Each
High density liver cancer with liver tissue array, including pathology grade, TNM and clinical stage, 208 cases/208 cores
Ask
View Details